PLAT and pulmonary embolism: The moderate pulmonary embolism treated with thrombolysis (MOPETT) trial was conducted to evaluate the role of a lower ‘safe dose’ of tissue plasminogen activator (tPA) with the hypothesis that lungs are highly sensitive to thrombolysis as they are the only organ to receive entire cardiac output [13].